Skip to content

PIVOTAL STUDY IN PATIENTS WITH BREAST CANCER TO INVESTIGATE THE EFFICACY AND SAFETY OF LA-EP2006 and NEULASTA ®

PIVOTAL STUDY IN PATIENTS WITH BREAST CANCER TO INVESTIGATE THE EFFICACY AND SAFETY OF LA-EP2006 and NEULASTA ®

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-119-11
Enrollment
26
Registered
2012-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

STUDY POPULATION WILL BE FORMED BY BREAST CANCER PATIENTS HISTOLOGICALLY DOCUMENTED WHERE NEOADJUVANT OR ADJUVANT TREATMENT WITH CHEMOTHERAPY WITH TAC IS INDICATED. THE STUDY WILL START WITH A SELECTI

Sponsors

Sandoz GmbH,
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. WRITTEN INFORMED CONSENT BEFORE ANY EVALUATION 2. BREAST CANCER PATIENTS HISTOLOGICALLY DOCUMENTED, WHO ARE ABLE TO RECEIVE NEOADJUVANT OR ADJUVANT CHEMOTHERAPY WITH IAE 3. ≥ 18 YEARS OLD WOMEN 4. ESTIMATED LIFE EXPECTANCE OVER SIX MONTHS 5. FUNCTIONAL STATUS OF EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) ≤ 2 6. APPROPRIATE PERFOMANCE OF BONE MARROW IN DAY 1 OF CYCLE 1, BEFORE ADMINISTERING CHEMOTHERAPY: • ANC ≥ 1.5 × 10⁹/l • PLATELET COUNT ≥ 100 × 10⁹/l • HEMOGLOBIN ≥ 1O g/dl 7. TOTAL BILIRUBIN WHICH IS NOT ABOVE THE UPPER LIMIT OF NORMAL (LSN), UNLESS THE PATIENT HAVE GILBERT SYNDROME 8. LEVEL ASPARTATE AMINOTRANSFERASE (AST) AND ALANINE AMINOTRANSFERASE (ALT) ≤ X ULN 9. LIVER ALKALINE PHOSPHATASE LEVEL ≤ 3 x ULN 10.CREATININA ≤ 1.5 X ULN 11.SERUM PREGNANCY TEST NEGATIVE SEVEN DAYS PRIOR TO THE RANDOMISATION IN ALL WOMEN IN REPRODUCTIVE AGE

Exclusion criteria

Exclusion criteria: 1. HISTORY OF CHRONIC MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME 2. HISTORY OR PRESENCE OF SICKLE CELL DISEASE 3. PRIOR OR CONCURRENT MALIGNANCY EXCEPT FOR NON-INVASIVE SKIN CANCER AND NON-MELANOMA, CARCINOMA IN SITU OF UTERINE CERVIX OR OTHER SOLID TUMOR TREATED WITH HEALING THERAPIES AND NO SIGNS OF RELAPSE FOR AT LEAST TEN YEARS BEFORE GOING INTO THE STUDY. 4. ANY SERIOUS ILLNESS OR SEVERE MEDICAL DISEASES THAT MAY INTERFERE WITH THE SAFETY, COMPLIANCE, THE ANSWER TO THE PRODUCTS ON RESEARCH AND EVALUATION, FOR EXAMPLE: • ACTIVE INFECTION WITHOUT CONTROL • CLINICALLY SIGNIFICANT ALTERATION OF LEFT VENTRICULAR EJECTION FRACTION (LVEF MUST BE DETERMINED BY ECHOCARDIOGRAPHY THAT MUST BE ABOVE NORMAL LOWER LIMIT OF THE RESPECTIVE CENTER) SEVERE DISEASE OF HEART VALVES, HEART ATTACK, Unstable Angina, UNCONTROLLED HYPERTENSION OR UNCONTROLLED ARRHYTHMIAS IN THE SIX MONTHS PRIOR TO ENTER THE STUDY • HISTORY OF SIGNIFICATIVE NEUROLOGICAL OR PSYCHIATRIC DISORDERS, INCLUDING PSYCHOTIC DISORDERS, DEMENTIA OR CONVULSIVE SEIZURES THAT AVOID TO UNDERSTAND OR GIVE INFORMED CONSENT.

Countries

United States

Contacts

Public ContactElizabeth Rospigliosi

I3 LATIN AMERICA PERU S.A.

elizabeth.rospigliosi@i3global.com616 4102

Outcome results

None listed

Source: REPEC (via WHO ICTRP)